Visvanathan et al. [33] showed that METTL3 mediated m6A modification plays a key role in the maintenance and dedifferentiation of glioma cells, revealing the basic role of METTL3 as a potential molecular target for the treatment of glioblastoma. Here, METTL3 is linked to glioma.